Skip to main content
Future Journal of Pharmaceutical Sciences
Fig. 5 | Future Journal of Pharmaceutical Sciences

Fig. 5

From: Comprehensive preclinical studies on the bioactivity of Orbignya phalerata Mart. (Babassu) and its derived products: a systematic review

Fig. 5

In vitro risk of bias assessment by domain. (legend) Q1—cells/strains from a validated repository or appropriately verified; Q2—technical repeats and controls inclusion; Q3—use of different cell lines/strains/reactions; Q4—comparable conditions between groups/assays; Q5—selective outcome reporting; Q6—comparison of different cell lines/strains/substances. Yes: low risk; Não: high risk; Unclear: uncertain risk. Questions adapted from Lewis et al. [20]

Back to article page